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Premature death from cardiovascular disease is especially high in patients with 
chronic kidney disease (CKD).  Vascular calcification is a potent risk factor for 
developing cardiac-related morbidity and mortality and is especially prominent within the 
CKD population. Deficiencies in serum levels of fetuin-A as well as inadequate 
production of matrix Gla protein (MGP) correlate inversely with the extent of vascular 
calcification and time spent on dialysis.  Fetuin-A is a well-known systematic regulator of 
bone metabolism and MGP is a local antagonist of bone forming proteins.  To meet the 
clinical need of at-risk patients prone to cardiac-related mortality. We propose a targeted 
protein therapy to treat arteriosclerotic arteries. The focus of this thesis was to 
characterize the binding interactions of fetuin-A with calcium mineral in a simulated 
body fluid and to study the in vitro effects of a fetuin vitamin K2 co-therapy on the 
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Statistics from the 2012 American Heart Association report show that each 
minute an American dies of a heart disease-related event [1]. Annually, cardiovascular 
disease is the cause of 1 in every 4 deaths in the United States [1]. Cardiovascular disease 
is also the leading cause of mortality for patients at all stages of chronic kidney disease 
(CKD), accounting for over fifty percent of mortality [2, 3]. Patients with CKD are more 
likely to die of cardiac related health events than to even reach end-stage renal disease 
(ESRD) [2].  
Longitudinal studies show that around thirty percent of the population suffering 
from cardiovascular disease also ends up with concurrent CKD [4]. This dynamic 
pathophysiological disorder of the heart and kidneys has been termed cardio-renal 
syndrome [4]. In recent years, studies have identified the following mutual risk factors 
that increase the morbidity among populations that suffer from cardio-renal syndrome: 
hypertension, diabetes, dyslipidemia, obesity, left ventricular hypertrophy, and vascular 
calcification [5-11]. In addition to the afore mentioned ‘traditional’ risk factors patients 
with CKD must also take into consideration the following kidney specific risk factors: 
proteinuria, anemia, inflammation, oxidative stress, mineral metabolism imbalance, high 
parathyroid hormone and low serum fetuin-A levels, and time on dialysis [12-20]. Heart 
failure at the onset of dialysis treatments in ESRD patients increases both the risk of early 
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death, death within 90 days of starting dialysis, and also long-term mortality [21]. A 2009 
study reports that after 3 years the heart failure mortality rate of dialysis patients was 
83% [21]. 
On average of 60-80% of dialysis patients experience severe vascular calcification 
contributing to cardiac morbidity and mortality where an estimated 50% of all ESRD 
mortality is caused by cardiovascular disease [2]. The U.S. Department of Health and 
Human Services estimates a 1.5 fold increase in ESRD patients by the year 2020; with no 
current therapy to treat vascular calcification a targeted therapy for treating the vascular 
arterial disease is necessary to maintain patients’ long term survival. The work presented 
in this here thesis was designed to address the clinical need of CKD patients with heart 
disease. A study of the elevated risk factors that exist for dialysis patients developing 
vascular disease, as well as an overview of the underlying biochemical factors were the 
basis for this thesis project.  
There is a strong clinical need for a minimally invasive therapeutic option to 
prevent and repair calcifying arteries without jeopardizing the already at risk patients who 
commonly suffer from co-morbidities. Based on current biomedical research findings it is 
the goal of this thesis work to show the feasibility of a protein therapy to prevent and or 
rescue calcifying vasculature. An intravenous targeted protein therapy could treat 
calcification negating any harmful effects of dialysis treatment on the cardiovascular 







There is clinical evidence that at-risk patient groups, like ESRD patients on 
dialysis, are at higher risk of developing cardiovascular disease and cardiac-related 
mortality due to the extent, severity and accelerated development of vascular calcification 
in the layers of the artery walls [22-25]. Vascular calcification (VC) is characterized by 
arterial stiffening, elevated systolic pressure and increased cardiac workload [11, 26]. 
There are two main types of vascular calcification, intimal and medial where the latter is 
most frequently observed in dialysis patients. Intimal calcification, or atherosclerosis, 
stems from damage to the endothelial lining coupled with an inflammatory and/or 
immune response that leads to plaque build-up and subsequent hardening eventually 
causing occlusion of the artery [9, 27, 28]. Medial calcification, also known as 
Mönckeberg’s sclerosis or arteriosclerosis [29, 30], directly affects the vascular smooth 
muscle cells (VSMCs) and is characterized by a loss of functional calcium receptors in 
the cell which leads to intercellular mineral imbalance and causes a change in VSMC 
phenotype and promotes osteogenic transformation of the VSMCs [12, 31-36]. Thus the 
deposition of hydroxyapatite mineral (basic calcium phosphate) within the VSMC matrix 
leads to hardening the medial layer and results in a loss of compliance of the artery. Both 
clinical studies of calcified arteries and in vitro calcification studies of VSMCs have 
shown that mineral imbalance contributes to differentiation of VSMCs into an osteogenic 
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phenotype by down regulating VSMCs contractile proteins and up-regulating bone matrix 
proteins, like bone morphogenic protein-2 (BMP-2), alkaline phosphatase (ALP), runt-
related transcription factor 2 (RUNX2) and down regulating native smooth muscle 
markers such as alpha smooth muscle actin (α-SMA), actin bundling protein transgelin or 
SM-22α, smooth muscle myosin heavy chain (SM-MHC) and local calcification 
inhibitors such as matrix gla proteins (MGP) and systematic inhibitors like fetuin-A [2, 
12, 37-39]. The altered expression of these proteins has been shown to be positively 
correlated to severity of calcification [12, 39, 40]. 
Previous medical perspectives on vascular calcification categorized it as a passive 
age-related process, wherein calcified plaques in the arteries were considered benign  
[23].  Existing correlations between vascular calcification and other non-age specific 
complications like stroke, myocardial infarction, comprised cardiac perfusion and 
impaired arterial dispensability have made it increasingly clear that vascular calcification 
is not a passive process and depending on the severity it can have serious life threatening 
consequences [23]. Once the relationship between vascular calcification and cardiac-
related morbidity and mortality had been established, the underlying mechanisms that 
lead to vascular calcification began to be studied. The pathology of vascular calcification 
has been paralleled to physiological bone formation [24] and is now regarded as an active 
cell-mediated process involving, cell death, loss of mineral inhibiting factors, and 
hydroxyapatite deposition in the underlying VSMC cell matrix similar to the mineral 
metabolism that occurs in the assembly of skeletal bone [41].  Recognizing the 
similarities between the processes of osteogenesis and ectopic calcification of soft tissue 
organs spurred breakthroughs in vascular calcification research on new ways to treat the 
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disease.  Key regulators in the skeletal biomineralization process have also been 
identified to play a role in the development of vascular calcification [24].  Proteins 
mediate bone growth and remodeling by actively inhibiting and promoting mineral 
deposition and antagonizing cellular expression of bone forming proteins [6, 42-44].  
Thus, understanding the mechanism(s) of regulatory proteins on mineral metabolism is 
imperative for the development of successful protein- based therapies to effectively treat 
and potentially reverse vascular calcification.  
For patients with end-stage renal disease (ESRD), malnutrition, dietary 
restrictions and the duration of dialysis treatments have shown a positive correlation with 
the progression of medial calcification [45, 46] when compared to age matched healthy 
controls, and non-uremic control groups [11, 17, 47-49]. We are proposing a novel 
therapy of targeted protein delivery to remedy medial calcification in ESRD patients. As 
heart healthy proteins like fetuin-A and MGP tend to be deficient and or under expressed 
in ESRD patients, early administration of a protein based therapy during the course of 
dialysis treatment is a viable therapeutic option.  By directing fetuin-A protein release to 
local sites of calcification and indirectly increasing local matrix gla protein expression, 
we can treat vascular calcification. This drug delivery system could actively prevent the 
formation of vascular calcification by halting the nucleation, growth, and aggregation of 
hydroxyapatite crystals and rescue the vascular smooth muscle cell phenotype of the 
affected arterial layer.  
Systematic Inhibitor: Human Fetuin-A 
In addition to the loss of VSMC phenotype, clinical studies of dialysis patients 
revealed a negative correlation between existing vascular calcification and decreased 
 
6 
serum concentrations of fetuin-A, a well-known systematic inhibitor of extra-skeletal 
calcification [12, 22, 50]. Low levels of serum fetuin-A are seen as predictors of 
cardiovascular morbidity in patients with ESRD [22, 51], and more specifically correlate 
with increased mortality in dialysis patients [29].  
Fetuin-A, also known as alpha2-Heremans Schmid glycoprotein, is a 
multifunctional serum protein that is naturally synthesized in the liver [52]. It acts as an 
indicator of chronic inflammation; helps to regulate bone metabolism by antagonizing 
transforming growth factor beta (TGF-β); provides over 50% of the inhibitory protective 
effect from mineral precipitation in serum, and has the ability to act as a chaperone 
protein by binding to and solubilizing calcium phosphate mineral colloids and facilitating 
in their removal from the cells [30, 51, 53]. In a study by Shroff et al.,  immunostaining 
revealed the presence of fetuin-A in the VSMCs of calcified arteries in patients with 
kidney disease [12].  Literature shows that fetuin-A uptake by VSMCs is dependent on 
extracellular calcium concentrations, and that under pathological concentrations of 
calcium, fetuin-A uptake by VSMCs was significantly increased [12, 51]. This finding 
indicates a potential role of fetuin-A in regulating mineralization outside of the skeletal 
system, and sequestration of fetuin from serum may be part of a secondary inhibitory 
response of the vasculature to the pathological calcification process [12, 51]. 
Local Inhibitor: Matrix Gla Protein 
There are also local inhibitors of calcification that exert their function in the 
tissues from which they are synthesized. One such group of proteins is MGP, which are 
vitamin K dependent and primarily synthesized by VSMCs and chondrocytes [54].  
Vitamin K is required to activate MGP via γ-carboxylation, a necessary modification that 
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enables MGP binding to BMP-2 [2, 38], thus inhibiting BMP-2 from exercising its 
function as a bone forming protein.  
In vivo studies by Luo et al on MGP deficient mice demonstrated the major role 
of MGP to inhibit soft tissue calcification [55]. In the study, the mice exhibited severe 
medial calcification leading to death at 8 weeks post-partum due to rupture of thoracic or 
abdominal aorta. Due to dietary restrictions and certain medications like the vitamin K-
antagonist Warfarin, given to dialysis patients there is insufficient vitamin K to activate 
MGP. It is common for the inactive form, under carboxylated MGP (ucMGPs), to 
accumulate in the VSMCs of dialysis patients [12]. This accumulation is often the nidus 
for hydroxyapatite mineral growth [2, 56]. Medicinal prescriptions and dietary 
restrictions are a common part of treatment for dialysis patients and unfortunately can 
lead to mineral metabolism imbalance which has been shown to directly cause vascular 
calcification in both clinical, in vivo and in vitro studies [35, 37]. It has been found that 
conditions like hypercalcemia and hyperphosphatemia create a more acidic pH that is 
conducive to soft tissue calcification [37, 57]. It has been shown that when the pH falls 
below 7.4 MGP synthesis is increased [56]. In vitro calcification studies demonstrate the 
ability of vitamin K treatments to reduce mineral deposits by over 60% from VSMC as 
well as potentially rescue native SMC phenotype by restoring expression of  native  SMC 






Vascular calcification can be deadly depending on the organ systems affected and 
the extent of calcification that is present. If the renal arteries are affected it can cause 
disease and the loss of kidney function can likewise lead to mineral metabolism 
imbalance that is further complicated by dialysis treatment. The altered mineral content 
causes a lower pH and ultimately decreases the active form of mineral inhibitors in the 
body, namely fetuin-A. As a result, serum fetuin-A which normally functions to prevent 
mineral formation on blood is endocytosed by VSMCs to help prevent calcification in 
soft tissues, causing the decrease in serum fetuin levels that is commonly found in 
dialysis patients [12, 59]. Clinical restriction for CKD patients require special diets that 
further promote calcification by limiting the necessary dietary vitamins needed for the 
VSMC to create mineral antagonist proteins like MGP. The lack of native mineral 
inhibitors present in serum and insufficient means to synthesize local inhibitory proteins 
increase the development of vascular calcification. Due to the similarities between 
skeletal bone and vascular mineral deposits, it has been proposed that vascular 
calcification can be reversed via demineralization, in a fashion that mimics physiological 
removal of calcified debris from bones [53].  
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A targeted intravenous therapy of fetuin-A would effectively halt the formation, 
growth, and aggregation of calcium minerals in the arteries; thus, preventing vascular 
calcification and potentially reducing the incidence of cardiac-related mortality. Our goal 
is to treat and prevent cardiovascular calcification in a minimally invasive manner that 
uses the native circulatory system to deliver this protein-based therapy specifically to 
sites of calcification.  We are proposing a targeted protein therapy to prevent vascular 
calcification with these specific aims:  
Specific Aims 
Aim 1: Characterize the binding mechanism, aggregation and stabilization effects of 
fetuin-A on calcium carbonate nanoparticles. 
Aim 2: Examine the inhibitory effect of a fetuin and vitamin K2 co-treatment to rescue 
native vascular smooth muscle cell phenotype and prevent calcification in an in 





PROTEIN-MINERAL COMPLEX FORMATION 
Biomineralization as an active process: A role for proteins 
Study of  protein involvement in the biomineralization process have resulted in 
new biomedical advances such as (i) targeted drug delivery systems (ii) dual purpose 
procedures used to simultaneously diagnose disease and administer therapy ; and (iii) 
development of biological stabilizers to optimize gene therapy and delivery of other large 
biomolecules into cells and tissues [60]. It has been shown that the incorporation of 
proteins and biomolecules with synthetic materials allows for increased biostability, 
biocompatibility, and an increase in successful biointegration with natural systems [61]. 
Bone growth and remodeling are processes that rely on protein activity to either inhibit or 
promote mineral deposition and other cell mediated activities. Understanding the 
mechanisms between proteins and nascent mineral is key to developing efficacious 
targeted protein therapies with the potential to treat vascular calcification.  
Mechanism of Inhibition by human Fetuin-A 
Fetuin-A has the ability to interact with mineral nuclei forming soluble colloidal 
particles, which we will refer to as calciprotein particles (CPPs) [43]. Under 
supersaturated mineral conditions fetuin-A prevents the precipitation of basic calcium 
phosphate (BCP) thus acting as a potent inhibitor of extracellular calcification. At a 
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cellular level fetuin-A aids in preventing apoptosis of vascular smooth muscle cells; 
however, the inhibitor protein can also aid in the binding of apoptotic bodies to 
neighboring cells and facilitate in cellular resorption of CPPs [30, 53]. Clearance of 
apoptotic bodies and CPPS reduces the potential for these bodies to act as a nidus for 
BCP. To gain a better understanding on the mechanisms of CPP clearance and fetuin-A 
function in stabilizing and solubilizing BCP colloids, researchers have studied fetuin-A’s 
ability to form colloidal bodies under supersaturated concentrations of calcium and 
phosphate in vivo and in vitro and in the affluent of peritoneal dialysis fluid. It has been 
observed that fetuin-A prevents direct precipitation of BCP mineral into the crystalline 
hydroxyapatite phase [43, 62]. Morphological changes in BCP mineral were observed by 
electron microscopy, showing that the addition of fetuin-A resulted in a brittle 
appearance of the precipitate formed [43]. The development of CPPs has been shown to 
be a time-dependent process that involves two phases and results in changes in 
appearance and an increase in diameter [62]. With regards to stability and formation 
kinetics of CPPs, it was found that the concentration of fetuin-A used versus the mineral 
ion concentration are factors that have a considerable effect on CPP size and the 
secondary ripening transition phase. Changes in protein mineral exposure time, and 
temperature resulted in feeble effects on subsequent CPP size [63]. A thorough 
characterization of the fetuin-A protein and knowledge of its chelating properties will aid 
in further understanding of its ability to control, stabilize and arrest the further 




Biominerals are naturally occurring organic-inorganic composites with a 
controlled hierarchical structure. Small molecules and acidic proteins play an essential 
role in the crystal lattice assembly of biomineral, ultimately determining the structure and 
mechanism of formation. Ambiguities exist between the cellular cues and types of 
proteins involved and the precise functions they play in controlling biomineral 
architecture, polymorphism and overall morphology. Much of this ambiguity could be 
resolved up by having a working knowledge and complete chemical analysis of the 
involved protein(s) [64]. Despite complete biochemical analysis of molecular and 
structural characterization of fetuin-A and extensive study of the various phases and 
transition states of calcium carbonate there have been no experimental studies on fetuin-
A’s ability to stabilize calcium carbonate (CaCO3) [65, 66]. It is our aim to characterize 
whether fetuin-A exhibits the same inhibition on biomineral precursors namely CaCO3 
and to gain further understanding of acidic protein parts and their effects on 
mineralization.   
 The objectives of this study were to characterize the biochemical interactions 
between fetuin-A and calcium-based nanoparticles in a simulated body fluid by (i) 
studying conformational changes of the protein upon binding to CaCO3 nanoparticles, (ii) 
by confirming protein adsorption and binding with CaCO3 nanoparticles, and (iii) to 
generate morphological identification of biocomposite systems for comparison/validation 




Materials & Sample Preparation 
Human fetuin-A was used as-received and reconstituted to a concentration of 0.1 
mg/mL (Sigma-Aldrich, St. Louis, MO; Biovendor, Asheville, NC). After preparation, 
Dulbecco’s modified Eagle’s medium (DMEM) (Corning, Lowell, MA) was filtered prior 
to use with a cellulose nitrate 0.22 µm pore membrane (Corning) followed by a 0.1 µm 
Acrodisc® Supor® membrane. DI water was used from an EMD Millipore Water 
purification system (Type I reagent grade water). Calcium carbonate (CaCO3) 
nanoparticles (15-40 nm) were used as-received and without any further modification 
(SkySpring Nanomaterials, Inc., TX, USA). For the fetuin-A/CaCO3 particles used in this 
work, DMEM was the solvent for all solutions. After two-stage DMEM filtering 
procedures, a small aliquot of DMEM was examined with DLS to guarantee a zero 
effective diameter. Then a solution with a concentration of 0.1 mg/mL of CaCO3 in 
DMEM was prepared (4 mL). This solution was then filtered using an Acrodisc 1.2 
micron Versapor membrane syringe filter, and sonicated for 5 minutes using a sonication 
bath (VWR) without heating. After sonication, DLS measurements were performed and 
the effective diameter of the sample was recorded. Fetuin-A protein (100 µL) was then 
added, at a concentration of 100 µg/mL. This solution containing CaCO3 and fetuin-A in 
DMEM was then studied using DLS, TEM, FTIR, XPS, UV-Vis, and SEM to examine 
the formation and evolution of the fetuin-A/CaCO3 complexes.  
Chemical Characterization 
A Nicolet 6700 FTIR spectrophotometer (Thermo Electron Corporation) with a 
He-Ne laser, MCT-A* detector, and KBr beam splitter with a Miracle-ATRTM accessory 
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(Diamond-ZnSe crystal, PIKE Technologies) was used for ATR-FTIR spectra collection. 
Fetuin-A, CaCO3, and fetuin-A/ CaCO3 nanoparticle complexes samples were deposited 
onto the ATR crystal from solution, the solvent was allowed to dry, leaving a thin sample 
film on the crystal’s surface. Infrared spectral data was then collected and analyzed using 
Omnic software (v8.1.10, 1992-2009, Thermo Fisher Scientific, Inc.), and a minimum of 
256 scans collected for each sample. X-ray photoelectron spectroscopy (XPS) was 
conducted using a PHI 1600 XPS surface analysis system (Physical Electronics, Mg Kα 
X-ray source (300 W, 15 kV), 45° take-off angle, PHI 10-360 spherical capacitor energy 
analyzer, and an Omni Focus II small-area lens. All samples were deposited from 
solution onto a clean gold-coated silicon wafer substrate. A total of 10 scans with 26.95 
eV pass energy across the 1100-0 eV range were analyzed for survey scans. High-
resolution XPS spectra consist of a minimum of 25 scans, at a 23.5 eV pass energy and 
0.1 eV step size. At least three spectra per sample were analyzed, and the averages are 
reported. Data analysis was performed using Origin Pro 2015.  
Morphological Characterization  
Scanning electron microscopy (SEM) was performed using a JEOL JSM-6500 
field emission scanning electron microscope (FE-SEM) operated at 10 keV. Sample 
preparation was performed in a similar manner to the XPS analysis; however, the gold-
coated silicon wafers were mounted on SEM holders using double-sided black carbon 
tape. High-resolution transmission electron microscopy (TEM) images were obtained 
using a JEOL 2100 at 200 kV. For TEM, sample droplets were placed on a carbon 
Formvar Cu grid 300 mesh (Electron Microscopy Science), and the liquid was evaporated 
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at ambient conditions inside a fume hood. CryoTEM images were collected using a JEOL 
1400 Biological TEM with a Gatan cryoplunge adapter.  
In-situ Characterization of Particle Diameters 
Dynamic light scattering (DLS) and zeta-potential phase-angle light scattering 
(PALS) measurements were conducted using a ZetaPALS instrument (659 nm 
wavelength, 90° detector, Brookhaven Instruments Corporation (BIC), Holtsville, NY). 
At least 5 measurements were taken for each sample, including 30 measurement cycles 
for each PALS experiment. Outlier analysis was performed at a 0.05 level of significance. 
Samples were analyzed at ambient temperature conditions (~22 °C). Results reported are 
based on Stokes-Einstein equation for the effective hydrodynamic diameter, or average 
mean diameter by number, and is specified for each analysis.  
Results 
Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy (ATR-
FTIR) 
The infrared absorption bands of the CaCO3 nanoparticles and fetuin-A protein 
were characterized as-received, using ATR-FTIR to identify their chemical composition 
Literature reports three distinct peaks for CaCO3 in a 100% calcite state [67]. Our 
findings are concurrent with reported literature, as we have established the presence of 
pure calcite by identifying the following bands and their respective calcite stretching 
vibrations: 1426 cm-1 (ν3), 876 cm-1 (ν2) and 712 cm-1 (ν4), see Figure 4.1a. 
Similarly, identifying peaks for neat fetuin-A were evaluated and to the authors 
knowledge this is the first study to report ATR-FTIR characterization of fetuin-A. IR 
analysis of proteins involves the detection of amide I, II and III spectral region [68]. 
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Deconvolution of the infrared spectra for the neat fetuin-A protein and the fetuin-
A/CaCO3 reveal a loss in characteristic vibrations of the glycoprotein as seen in (Figure 
4.1b-c). The differences in IR spectra of the amide complex bands between fetuin-A and 
fetuin-A/ CaCO3 peaks will be discussed herein. Additional identification of other 
characteristic peaks for the fetuin-A protein are discussed in Appendix Figure A.1 and 
summary table of these bands is available in Appendix Table A.2. As seen in Figure 4.1b 
an evaluation of the amide I region for the protein spectra reveals four distinct peaks in 
the range of 1600-1700 cm-1 wavenumbers. The peaks observed at 1700 cm-1 and 1654 
cm-1 correspond to the C=O stretching vibrations. Specifically the peak seen at 1700 cm-1 
is indicative of glutamic acid or asparagine amino acids present in the protein [69]. The 
α-helical secondary structure of the protein and/or the C=O stretching vibrations from the 
arginine amino acids can be identified by the peaks seen at 1654 cm-1 which is typical of 
soluble proteins [69-71]. Evidence of protein secondary structure was seen in the form of 
peaks at 1629 cm -1 and 1601 cm -1 which correspond to protein β-sheets and 
intermolecular β-sheet turns respectively [68, 69]. Analysis of the amide II region for 
neat fetuin-A revealed an absorption peak at 1543 cm -1 which is indicative of a primary 
amine deformation (Figure 4.1b) possibly occurring in tryptophan side chains [69, 72].  
The peak at 1515 cm-1 represents C-O stretching in the alcohols of amino acid side chain 




Figure 4.1 ATR-FTIR spectra comparing neat fetuin-A, CaCO3 and fetuin-A/CaCO3 
complex samples 
A) ATR-FTIR spectra overlay for fetuin-A, CaCO3 and fetuin-A/CaCO3 complex 
B) Deconvoluted spectra showing amide I and amide II region for neat fetuin-A 
C) Deconvoluted spectra showing amide I and amide II region for fetuin-A/CaCO3 
The addition of fetuin-A to CaCO3 nanoparticle samples resulted in notable 
changes of the protein IR absorption peaks. The loss of two out of four peaks in the 
amide I region indicate that binding of the protein to the CaCO3 nanoparticles imparted 
changes in the proteins chemical structure. Upon combining the protein with the CaCO3 
sample IR spectra revealed characteristic peaks of asparagine (C=O) amino acid groups at 
1640 cm -1 and 1675 cm -1 [69], see Figure 4.1c. The loss of characteristic peaks in the 
amide I region upon analysis of the fetuin-A with CaCO3 sample point to a potential 
binding mechanism between fetuin-A and CaCO3 nanoparticles involving protein β-
sheets and loss of α-helical turns. FTIR analysis of proteins onto a biomaterial surfaces 
reveal that β sheet vibrations tend to absorb between 1640 and 1620 cm-1 and that 
absorbance readings ~1670cm-1 correspond to β-turns [70, 71]. Moreover bands in the 
 
18 
1670-1695 cm-1 region correspond to anti-parallel β-sheet structure [71]. The peaks that 
were lost in the neat fetuin-A analysis, 1654 cm-1, 1629 cm -1 and 1601 cm -1 
wavenumbers, correspond to the amino acid residues of the protein secondary structure 
[43]. The findings concluded by Heiss et al. revealed that it is the amino acid residues of 
the fetuin-A protein that are responsible for the proteins affinity for calcium and in this 
case the adsorption onto the CaCO3 nanoparticle substrate [43]. With regards to the 
amide II region, comparison of the IR spectra for the fetuin-A with CaCO3 nanoparticles 
and the neat fetuin-A sample shows both the loss of characteristic peaks within the amide 
II region and a noticeable increase in wavenumber of the detected peak from 1543 cm-1 to 
1586 cm -1. The changes in absorbance indicate the binding of fetuin-A to the CaCO3 
substrate that resulted in changes to protein secondary structure as illustrated by loss of 
absorbance of tyrosine and tryptophan amino acid side chains, 1515 and 1543 cm-1 
respectively, and led to the detectable absorbance of amino acid glutamine (1586 cm-1) 
[69, 70, 72, 73]. 
X-ray Photoelectron Spectroscopy 
Elemental composition of the sample surface, namely CaCO3 and fetuin-A/ 
CaCO3, were evaluated using X-ray photoelectron spectroscopy (XPS). As expected 
elemental surface analysis of the CaCO3 nanoparticles revealed carbon (C, 32.8 ± 3.1), 
calcium (Ca, 18.4 ± 3.8%), and oxygen (O, 48.9 ± 0.9%) which were close to theoretical 
values for CaCO3 composition (20% C, 20% Ca, and 60% O) and can be seen in Figure 
4.2. The graph in Figure 4.2 shows an overlay of XPS results of elemental detection of 
the CaCO3 and fetuin-A with CaCO3 samples. The deviation in the carbon content for the 
elemental composition of CaCO3 nanoparticles is considered adventitious and is due to 
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preparation of XPS samples in open air prior to analysis and can be otherwise neglected 
[74]. Similarly elemental surface analysis of the fetuin-A/ CaCO3 samples revealed 61.4 
± 0.6% C, 31.3 ± 0.8% O, and 7.3 ± 1.5% N. The detection of nitrogen and the increase 
in the carbon content, despite the presence of adventitious carbon, indicates the addition 
of glycoproteins, confirming the presence of fetuin-A on the surface of CaCO3 particles 
[75]. The absence of elemental Ca within the outermost10 nm layer of fetuin-A/ CaCO3 
sample surface suggesting that CaCO3 has been encased by a fetuin-A protein coat, 
resulting in a stabilized fetuin-A/ CaCO3 complex structure.  
 
Figure 4.2 Overlaid XPS scans for neat CaCO3 nanoparticles and fetuin-A/CaCO3 
protein nanoparticle samples 
 
Evident from the different IR spectra discussed previously, the formation of the 
fetuin-A/ CaCO3 complex resulted in chemical changes in the protein structure. High-
resolution XPS analyses of elemental calcium, carbon, oxygen and nitrogen enabled us to 
identify specific functional groups and chemical bonds that were altered as a result of 
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complex formation. In reference to calcium the high resolution scans can be seen in 
Figure 4.3 A-B, showing the results for neat CaCO3 nanoparticles and for fetuin-A/ 
CaCO3 complex.  
 
Figure 4.3 High resolution XPS scans for elemental calcium  
A) Neat CaCO3 nanoparticle samples 
B) Fetuin-A/CaCO3 protein and nanoparticle sample 
For the neat CaCO3 nanoparticles, Figure 4.3A, there were two clearly identifiable 
calcium peaks at 346.5 and 350.0 eV, which correspond to the Ca 2p3/2 and Ca 2p1/2 
photoelectron lines, respectively [76, 77]. Upon analysis of the high resolution XPS 
calcium scan for the fetuin-A/ CaCO3 complex a loss of the peaks correlating to the Ca 
2p3/2 and Ca 2p1/2 photoelectron lines was observed (Figure 4.3B). The lack of 
elemental calcium detected in the fetuin-A with CaCO3 sample seen in Figure 4.3 
supports the hypothesis of the formation of a stabilized fetuin-A protein coat over the 
CaCO3 nanoparticle surface.  It is known that fetuin-A binds to calcium with high affinity 
and the undetectable calcium in this XPS surface analysis supports our conclusion that 
fetuin-A has adsorbed onto the CaCO3 nanoparticle surface. With regards to the other 
elements, carbon, oxygen and nitrogen the high resolution XPS scans also indicate 
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adsorption-related transitions in peaks associated with identifying photoelectron lines.  
For carbon, see Figure 4.4 A-B, the C 1s peak at 285.3 eV corresponds to C-C/C-H bonds 
and is found in both neat CaCO3 and fetuin-A/ CaCO3 complex samples respectively.  In 
order to calibrate the scans for charge compensation the C1s peak was used as a reference 
[78]. For the neat CaCO3 sample the peak at approximately 290 eV represents carbonate 
((C-O)3) from CaCO3 [76]. The additional high resolution carbon peaks at 286.8 eV and 
at 288.7 eV observed for the fetuin-A/ CaCO3 sample (see Figure 4.4B) confirm the 
presence of fetuin-A glycoprotein on CaCO3 particles. The peak at 286.8 eV is indicative 
of C-O, C-N and/or to an N-C-O bond [73, 79]. The 288.7 eV peak represents N-C=O, 
and is consistent with the carbon of an amide functional [79, 80].  
 
Figure 4.4 High resolution XPS scans of elemental carbon and oxygen.  
Carbon scan for (A) neat CaCO3 nanoparticles and (B) fetuin-A/ CaCO3 protein 
nanoparticle samples 




Results for the neat CaCO3 nanoparticle high-resolution oxygen scan (see Figure 
4.4C) reveal a O 1s peak at 528 eV binding energy corresponding to carbonate ((C-O)3) 
oxygen in CaCO3 [77]. Analysis of the fetuin-A/ CaCO3 sample (see Figure 4.4D) show 
that complex formation resulted in two distinct chemical shifts for the high resolution 
oxygen scan. The peak observed at 530.6 eV represents oxygen in amino acid chains 
[81],  and the 532 eV peak can be attributed to either a C=O peptide bond or to –OH 
bonds which could be residual contaminants left after the solvent evaporated [82-85].  
 
Figure 4.5 High resolution XPS for elemental nitrogen  
(A) Neat CaCO3 nanoparticles  
(B) Fetuin-A/ CaCO3 protein nanoparticle sample. 
Lastly, the detection of a N 1s photoelectron line in the  fetuin-A/ CaCO3 sample 
and not in the neat CaCO3 high-resolution nitrogen scan confirms fetuin-A presence on 
the outer surface of fetuin-A/ CaCO3 complexes (see Figure 4.5 A, B) [83]. The results of 
these XPS data support those obtained from ATR-FTIR and indicate the presence of 
fetuin-A on the exterior surface of fetuin-A/ CaCO3 samples, indicative of a stabilizing 




Morphological characterization show the CaCO3 nanoparticles have a tendency to 
aggregate, this is likely due to the fact that the samples were allowed to dry on the grid 
SEM grid without a stabilizer (see Figure 4.6 A). The CaCO3 nanoparticles showed a 
rhomboid-like structure under SEM analysis (see Figure 4.6 B). The results obtained 
from TEM (see Figure 4.7 A) corroborate those of SEM and show densely packed 
clusters of aggregated CaCO3 nanoparticles. The rhombohedral shape is evident upon 
higher magnification with TEM (Figure 4.7 B) and is representative of nanosized CaCO3 
crystals within a larger-scale aggregated structure. These images of CaCO3 nanoparticle 
morphology support those found in literature on aggregation of the mineral phase [86].  
 
Figure 4.6 SEM image of neat CaCO3 nanoparticles. 




Figure 4.7 TEM images ofaggregated neat CaCO3 nanoparticles. 
At high resolution a rhombohedral-like structure is observed which is characteristic of 
nanoparticle materials. Scale bar is equal to 100 nm and 50 nm for images A and B 
respectively 
As discussed in the beginning of this chapter fetuin-A is said to absorb onto 
aggregated CaCO3 to form a complex. Once fetuin-A protein is added to CaCO3 particles 
the morphology changes and SEM images show protein-stabilized CaCO3 aggregates 
(Figure 4.8 A, B) As seen in the same image, globular fetuin-A begins to adsorb onto the 
CaCO3 nanoparticle aggregates and the resultant complexes range in size from 400-600 
nm after a 48 hour incubation period. Interesting to note that the rhomboid like 
morphology of the neat CaCO3 nanoparticles was lost, signifying transitions in the 




Figure 4.8 SEM images of CaCO3/fetuin-A protein nanoparticle complex samples. 
The morphology shown here is move ovoid in appearance compared to neat CaCO3 
nanoparticles and includes both large and small aggregates. Scale bar is equal to 1 µm 
and 100 nm for images A and B respectively. 
Research on calcium carbonate interactions with acidic protein residues have 
determined that binding of the protein to the substrate occurs parallel to the calcium 
plane, thus altering mineral morphology and giving it a smoother texture [87]. Studies 
have shown that CaCO3 mineral microstructure can be dramatically altered by proteins to 
generate various distinct crystalline phases [88]. Ultimately, the loss of rhombohedral 
structure upon formation of fetuin-A/ CaCO3 complexes supports the de-aggregation and 
stabilization CaCO3 particles when fetuin-A adsorbs onto the CaCO3 aggregate. 
High resolution TEM analysis was employed in order to evaluate the morphology 
within the protein mineral complexes formed. Detection of three distinct morphologies 
depict possible intermediate stages of stabilized complex development and protein 
binding interactions between fetuin-A and CaCO3 nanoparticle structures. The first 
morphology depicted below (Figure 4.9A), is suggestive of an intermediate state in which 
fetuin-A proteins are bound to small CaCO3 particles inducing phase transitions. The 
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morphology observed in Figure 4.9A represents more stable complexes and has an ovoid 
appearance which is supported by the morphology seen in SEM results and further 
confirmed by the DLS results to be presented shortly (Figure 4.10 A, B). The next 
morphology (see Figure 4.9B) that was observed shows needle like protrusions coming 
from the corona of a lesser dense core with smaller CaCO3 particulates diffusing from the 
exterior of the structure (see Figure 4.9B inset). Figure 4.9 C shows what we believe to 
be CaCO3 particle aggregates encased by a stabilized protein coat.  
  
Figure 4.9 Early, intermediate and stabilized stages of fetuin-A/CaCO3 protein 
nanoparticle complex formation. 
A) Early fetuin-A/CaCO3 complex formation 
B) Intermediate stabilization stage of fetuin-A/CaCO3 complex formation; inset reveals 
the solubilization of CaCO3 mineral by fetuin-A protein, scale bar = 200 nm. 
C) Stabilized fetuin-A/CaCO3 protein mineral complex. 
In situ characterization of Fetuin-A/ CaCO3 complexes 
Analysis of the fetuin-A protein and fetuin-A/ CaCO3 complex molecular 
absorbance and hydrodynamic diameter were assessed in situ using dynamic light 
scattering (DLS) and UV-Vis spectroscopy while in an aqueous simulated body fluid 
(DMEM). The DLS hydrodynamic diameter of the fetuin-A protein was 6 ± 0.74 nm in 
DMEM (Figure 4.10 A,B), and relates well with literature reports of 4.2 nm for fetuin-A 
corresponding to an ASHG monomer [89]. Number-averaged mean diameters for the 
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protein samples were reproducible, as indicated by the plot intensity for multiple runs 
(Figure 4.10B).  
 
Figure 4.10 Fetuin-A stabilizes CaCO3 nanoparticles by forming a complex and 
reducing hydrodynamic diameter of nanoparticle aggregates.  
A) Average effective diameter increases significantly from the neat CaCO3 nanoparticle 
aggregates to the fetuin-A/CaCO3 protein nanoparticle complex. 
B) Number intensity readings of fetuin-A protein size are shown indicating protein 
diameter stability in DMEM solvent. 
The results for the effective particle diameter (using the Stokes-Einstein equation) 
support the adsorption of fetuin-A onto the aggregated CaCO3 structures and ultimately 
the formation of a fetuin-A/ CaCO3 complex. The increase in the effective diameter of 
the CaCO3 nanoparticles from the adsorption of the fetuin-A protein can be seen in 
Figure 4.10A. A stable zeta potential reading of -24.2 ± 1.8 mV for the surface CaCO3 
particles was increased to (-0.1 ± 9 mV) upon addition of fetuin-A protein confirming the 
fetuin-A adsorption process.  
Using UV-Vis spectroscopy neat fetuin-A protein was compared to fetuin-A/ 
CaCO3 complexes in solution. As compared to neat fetuin-A, a minor shift in maximum 
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molecular absorbance in the 270-280 nm region as well as a decrease in absorbance 
maxima occurs as fetuin-A/ CaCO3 complexes form in water (Figure 4.11). UV-visible 
spectroscopy absorption spectra in the ~270-280 nm region indicate that the disulfide 
bonds and the aromatic amino acids (tryptophan and tyrosine) of the fetuin-A protein are 
altered upon absorption of fetuin-A to the CaCO3 nanoparticles [90]. This data 
corroborates the FTIR spectral data (see Figure 4.1) with the loss of the distinctive amide 
II peaks (1515 and 1543 cm-1) which match corresponding absorbance readings for 
tyrosine and tryptophan and literature findings that the amino acid residues in fetuin-A 
are responsible for the protein affinity to calcium substrates [91, 92]. 
 
Figure 4.11 UV-Visible Spectroscopy of neat fetuin-A compared to fetuin-A/ CaCO3 
complexes 
 
To further examine the long term stabilizing effects of fetuin-A on CaCO3 
agglomerates the particle morphologies were analyzed after two months with in situ TEM 
to avoid artificial particle shrinkage/distortion due to drying effects. Figure 4.12, 
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corresponding to the 2 month sample, shows small particles ranging from ~11-110 nm in 
diameter; the range of sizes is possibly due to decomposition of CaCO3 nanoparticle 
aggregates. 
 
Figure 4.12 Cryo-TEM of fetuin-A/CaCO3 incubated for two months reveals small 
stabilized complex aggregates. 
 
Conclusion 
With the study the adsorption, binding and stabilizing effects of fetuin-A protein 
on CaCO3 nanoparticles have been demonstrated. Moreover, characterization of the 
chemical and morphological changes that occur during the interaction between the acidic 
protein and the CaCO3 substrate have been closely examined and reported herein.  CaCO3 
is an attractive biomaterial for potential use in biomedical applications. The results of this 
study can help evaluate how varying levels of fetuin-A mediate pathological calcification 
while in the presence of CaCO3 particles in addition to the well-known basic calcium 
phosphate.  Both the biochemical and structural characterizations of CaCO3, the 
glycoprotein fetuin-A, and fetuin-A/ CaCO3 complexes provide a foundation for further 
studies examining the functional groups and protein segments  involved in short- and 
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long-term interactions and stability of mineral growth and aggregation. The results of this 
work confirm that fetuin-A is a potent stabilizer of calcium ions despite the absence of 
phosphate ion, as has been purported elsewhere. The formation of a stabilized fetuin-A/ 
CaCO3 complex has been shown to be time-sensitive, with the mechanism including an 
initial adsorption, followed by a complex stabilization period, and then destabilization 
and solubilization of the mineral agglomerates. This mechanism has been explored using 
FTIR and XPS for chemical characterization, SEM and TEM to examine the morphology 
and structural changes, and DLS, cryo-TEM and UV-Vis for in situ characterization of 
the complex formation and development. The results from this study support the potential 
use of fetuin-A  in the development of biomedical therapeutics targeting cardiovascular 




FETUIN AND VITAMIN K2 ADDITIVES TO PREVENT VASCULAR 
CALCIFICATION 
Vascular calcification is a complex condition further complicated by co-
morbidities involving disorders of metabolism and age-related illness. Elevated serum 
phosphate levels (>1.4 mM), hyperphosphatemia, is a common condition seen in CKD 
patients and has been correlated to severity of vascular calcification [23]. There are many 
factors to consider when assessing the pathological mechanisms that take place. The 
underlying cellular matrix and surrounding cells involved in arteriosclerosis, as well as 
phenotypic switching that occurs among the vascular smooth muscle cells make 
assessment of the condition a difficult one to properly model. To this end, knock-out 
animal models and in vitro cultures have been rather successful in identifying key 
mediators in the vascular calcification process [3, 7-9, 93]. Increased phosphate levels 
lead to the calcification of smooth muscle cells in vitro and cause increased expression of 
osteogenic markers such as core binding factor alpha or RUNX2 and osteocalcin [94].  
Phosphate levels are mediated via the sodium-dependent phosphate co-transporter 
(NPC) protein. Blocking NPC function with an inhibitor has shown a dose-dependent 
decrease in inorganic phosphate (Pi) induced calcification of smooth muscle cells [94]. 
The NPC protein is responsible for the resorption of the majority of phosphate filtered 
through the glomerulus. The sodium potassium channels in turn are regulated by 
 
32 
parathyroid hormone (PTH) which acts to excrete excess phosphate into the urine. With 
progressive kidney disease, declining glomular filtration rates lead to a decrease 
phosphorus excretions contributing to hypophosphatemia. The increased serum levels of 
phosphorus cause a decrease in serum calcium levels that consequently contributes to an 
increase in parathyroid production. As one or both ion levels of calcium and phosphorus 
increase in serum an insoluble complex, hydroxyapatite forms [95].With significant 
increases in calcification there is a loss in expression and or function of calcium receptors 
that control levels of intracellular calcium [96].  For this study we will use Pi for the 
development of an in vitro vascular calcification model to study the potential of potent 
mineral inhibitors fetuin and matrix gla protein (MGP) (see Chapter II). Briefly, fetuin-A 
deficiency is common in dialysis patients and low levels of fetuin correlate with 
increased risk of cardiac related mortality in this patient population.  Fetuin-A is a well-
studied systematic regulator of biomineralization and has a binding affinity for calcium 
mineral.  The fetuin-A protein has the ability to form protein mineral complexes and 
solubilize basic calcium phosphate precipitates and aids in cellular clearance of mineral 
debris [30, 51, 53]. Study of local mineralization inhibitors like MGP, show that MGP is 
an antagonist of bone forming proteins and protects the native VSMC phenotype [2, 38]. 
Vitamin K2 is necessary for production of activated, mineral inhibiting MGP [2, 38]. As 
vitamin deficiency and prescription blood thinners like Warfarin cause vitamin K2 
deficiency in dialysis patients the inactivated forms of the MGP create nucleation sites 
for mineral deposition [12, 56]. Further examination of the matrix vesicles of vascular 
smooth muscle cells found protein mineral complexes containing basic calcium 
phosphate fetuin-A and MGP. This study aims to (i) assess the extent to which 
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calcification can be halted and or reversed, (ii) whether or not the fetuin and vitamin K2 
co-treatments have an additive affect to rescue the native VSMC phenotype changes 
induced by calcifying media. Restoration of inhibitory proteins to the system could 
reestablish the protein and vitamin deficiencies in dialysis patients whilst preventing the 
development of vascular calcification and reducing the risk of cardiac-related morbidity 
and mortality. The combined treatment using two potent mineralization inhibitors (fetuin 
and MGP indirectly) may also reverse calcification and possibly restore the cellular 
functions of the VSMC by rescuing the native phenotype.  
Experimental Section 
Materials & Sample Preparation 
VSMC Culture and Morphology. Primary human aortic vascular smooth muscle 
cells (ATCC, Manassas, VA) of passage 6-8 were cultured in Dulbecco’s Modified 
Eagles Medium (DMEM) with 10% Fetal Bovine Serum, and 1 % 
penicillin/streptomycin). Cell morphology was visualized using light microscope. At 
passage 8, cells were seeded into 6-well plates with 3 mL of standard growth medium per 
well. Medium was changed every 2-3 days until cells reached 80% confluence in each 
well at which the time point of the study began, marked day 0. Experimental groups were 
given calcification medium (standard growth medium supplemented with 3 mM dibasic 
inorganic phosphate (Pi) from days 0-7. On day 7, calcification medium was removed 
from the experimental groups that then received protein treatments in the form of 
standard growth medium supplemented with 10µM fetuin, 1µM vitamin K2, or both for 
another 7 days (n=4). Control groups include VSMCs cultured with and without 
calcification medium for 14 days. (n=4) 
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Quantification of Mineral Deposition.   
On day 14, samples were prepared for atomic absorption spectroscopy (AAS) in 
order to quantify calcium content of the cell cultures. Cells were treated with 0.6 N HCl 
for 24 hours. The HCL supernatant was prepared for atomic absorption analysis via 
addition of nitric acid and potassium. The calcium content of the cell layer was 
normalized to protein concentration using BCA Protein Assay Kit (Pierce, Waltham, 
MA).   
Alkaline Phosphatase activity.  
Alkaline phosphatase (ALP) activity of cell supernatants was measured from day 
7 and day 14 samples of all groups was measured using a Colorimetric Alkaline 
Phosphatase Assay Kit (Abcam, Cambridge, MA). Absorbance of p-nitrophenyl 
phosphate (pNPP) was read at 405 nm wavelength and results were normalized to 
standards. Sample background controls were used in order to correct for the red color of 
sample supernatant when interpreting the results of the colorimetric output.  
Scanning Electron Microscopy. 
Following treatment, cells were fixed with Karnovsky’s fixative in 0.1 M sodium 
cacodylate buffer and then processed for imaging. Imaging was performed using a JEOL 
JSM-6500 field emission scanning electron microscope (FE-SEM) operated at 10 keV. 
Energy Dispersive X-Ray Spectroscopy (EDS) was used to quantify the elemental 
composition of regions of interest. 
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Statistical Analysis.  
Comparison between control groups and experimental groups was performed 
using ANOVA and post-hoc Tukey HSD. 
Results 
Quantitative Calcium Analysis 
AAS was used to measure the amount of elemental calcium in the in vitro 
cultures. Quantitative analysis of calcium content in cells was found by extrapolation 
from the absorbance versus concentration plot obtained by the standard curve. The 
amount of calcium deposited by the cells that calcified for the entire length of the study, 
was significant when compared to all other groups including the 7 day calcified cells 14 
day untreated (universal control) cells and the cells that received protein treatments 
(10μM fetuin and or 1μM vitamin K2). There were no statistical differences observed 
between treated groups and the universal control; however, the comparable level of 
calcium content found in protein/vitamin treated cells and the universal control supports 
the ability of fetuin and or vitamin K2 treatments to significantly inhibit calcification 




Figure 5.1 Elemental calcium content of human vascular smooth muscle cells treated 
with calcifying media and subsequent calcification inhibitors. 
 
Protein Analysis 
Alkaline phosphatase assay is designed to measure ALP activity, and is an early 
bone indicator of alterations in VSMC native phenotype. The assay uses pNPP as a 
phosphatase substrate that changes color when dephosphorylated by ALP. As seen in 
Figure 5.2, ALP activity is highest on day 7 of VSMC exposed to calcifying media. The 
day 14 universal control group that received standard growth media as well as the vitamin 
K2 only treatment group have miniscule amounts of detectable ALP activity. Statistical 
analysis of the ALP results showed that there was no significant variation among 




Figure 5.2 Alkaline phosphatase activity in human vascular smooth muscle cells 
treated with calcifying media and subsequent calcification inhibitors. 
 
The results of this study further support the ability of fetuin and vitamin K2 to 
prevent calcification and moreover the ability to rescue the native VSMC phenotype as 
seen by the decrease in ALP activity from the first week of receiving calcifying media to 
the second week of receiving media supplemented with calcification inhibitors (fetuin, 
vitamin K2 and a co-treatment of fetuin and vitamin K2).  
Microscopy 
Scanning electron microscopy was used to visualize the calcium deposition. 
Morphological characterization of the control, calcified and treated cell groups can be 
seen in Figures 5.3-5.6 below. Characteristic morphology for the VSMC is observed in 
the images as well as rounded nodules which appear to be apoptotic bodies or perhaps 




Figure 5.3 Electron microscopy image of healthy and calcified human vascular 
smooth muscle cells at day 14.  
Left image is of human vascular smooth muscle cells that received standard growth 
medium for the entire length of the study.  The cells on the right received calcification 
media for the length of the study. Images taken at 3500x magnification, scale bar = 10 
µm. 
 
Figure 5.4 Electron microscopy image of calcified human vascular smooth muscle 
cells treated with calcification inhibitors fetuin or vitamin K2.  
Above images are of human vascular smooth muscle cells that received calcification 
media days 0-7 of the study and were subsequently given standard media supplemented 
with calcification inhibitors on day 8-14 of the study; (left) cells given fetuin 
supplemented media and (right) vitamin K2 supplemented media. Images taken at 3500x 




Figure 5.5 Electron microscopy image of calcified human vascular smooth muscle 
cells co-treated with fetuin/vitamin K2  
After receiving calcification media days 0-7 of the study the cells were given standard 
media supplemented with both calcification inhibitors on day 8-14 of the study; Images 
taken at 3500x magnification, scale bar = 10 µm. 
Energy dispersive X-ray Spectroscopy (EDS) was also performed on the SEM 
samples the results of these EDS scans can be seen in Appendix Figures A.2-A.6. 
Conclusion 
This study confirms the potential use of fetuin-A or vitamin K2 for the effective 
development of a protein based therapy to treat vascular calcification. It was 
hypothesized that fetuin and vitamin K2 would have an additive effect in preventing and 
or reversing calcification in cells exposed to calcifying media for one week and then 
treated with a combination of calcification inhibitors for a subsequent week. From the 
results of the AAS on calcium deposition alone, no conclusions can be drawn about the 
additive effects of a fetuin/vitamin K2 co-treatment to synergistically reverse the amount 
of calcium deposited. The respective protein treatments as well as the combined protein 
treatment were significantly effective in halting further calcification of the vascular 
smooth muscle cells. 
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  Though the effects of combined fetuin and vitamin K2 did not appear to have an 
additive effect on reducing calcium deposition, the results of SEM images do show 
promise of the co-therapy to remove calcium deposits in cells as the electron microscopy 
images of the treated groups were comparable to the healthy control group. The protein 
treated groups received calcifying media for one week prior to getting the respective 
treatments of 10 μM fetuin and or 1μM vitamin K2. When comparing the ALP activity of 
the 7 day calcified cells to the treated groups there is notable reduction in detectable ALP 
activity. Moreover the cells that received calcifying media for an additional week 14 day 
calcifying control also had higher trend in detectable ALP activity than all groups that 
received protein treatments. The lack of statistical evidence to support the ALP results 
warrants a larger sampling group for future studies. Whether or not fetuin and vitamin K2 
co-therapy have the ability to rescue the native VSMC phenotype can unfortunately not 
be concluded by the results obtained from the ALP assay, an indicator of early osteogenic 
transition of VSMC. The SEM images support he results found from the atomic 
absorption spectroscopy where the fetuin and vitamin K2 treated groups are comparable 
to the universal control and show significantly less deposits than the calcified VSMC. 
The overall results support the feasibility of a fetuin therapy to have a potent 
effect on vascular calcification. Adverse effects of this protein/vitamin co-treatment is not 
expected since: (i)this study models the toxicological aspect of restoring fetuin protein 
concentration and vitamin K2 levels to that of normal physiological levels and (ii) most 
CKD patients have protein and vitamin K2 deficiencies which positively correlate to the 
severity and progression of cardiac-related morbidity and mortality.. None the less it 
would be interesting to observe how well this co-therapy would affect vascular 
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calcification at the cellular level in a uremic model with serum starved cells. To this end, 





Effective therapies have the ability to both treat and prevent the occurrence of 
diseases. The work presented in this thesis shows that a co-treatment of fetuin and 
vitamin K2 has the potential to be highly effective at preventing the progression of 
calcification. In order to determine the potential of this therapy to effectively treat 
vascular calcification, a thorough analysis of VSMC phenotype before and after therapy 
is necessary. The work herein could be further enhanced by making the following 
recommendations: 
1. Expand the experimental design to include:  
a. Pharmacological study where treatment groups receive incremental amounts 
of fetuin and vitamin K2 treatment to determine the effective dose and to 
examine the effect of low vs high dose on the ability to treat calcification.  
b. Treatments applied at varying time points in the calcification study before 
calcification occurs during calcification and after the cells have calcified for a 
longer period of time in order to compare the ability of treatment groups to 
reverse calcification after one and two weeks of receiving inorganic 
phosphate supplemented media. 
c. Develop a uremic model of vascular calcification to test the effective ness of 
a fetuin/vitamin K2 co-treatment to properly model vascular disease in 
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patients with chronic and or end-stage renal disease. Serum starve cells prior 
to treatment to properly mimic a malnourished/ protein deficient state. 
2. Study Osteogenic Transition/Rescue of Calcified Vascular Smooth Muscle 
Cells 
a. Perform Western blot analysis after cells have received treatment to assess 
the ability of fetuin and vitamin K2 to restore native VSMC phenotype and 
reduce the expression of osteogenic markers like RUNX2 and native VSMC 
phenotype markers like MGP and SM α-actin.  
b. Isolate native protein-mineral complexes from cell culture supernatant 
before, during and after calcification and protein treatments to characterize 
fetuin-mineral complexes [97, 98]. 
In order to progress to an actual clinical therapy, this project must be further 
developed to include delivery mechanisms sufficient for in vivo testing. If fetuin delivery 
is to be developed into a therapy it is essential that this multifunctional protein be 
encapsulated in a delivery vehicle. Protein delivery systems made of self-assembling 
polymersomes are ideal carriers for targeted protein therapy. Variations of polymer block 
combinations of polyethylene glycol and poly ɛ-caprolactone (PEG-b-PCL) grafted with 
a stimuli responsive polymer are a common choice for developing targeted protein 
therapies due to the biocompatibility, biodegradability and tailorability. With regards to 
arteriosclerosis and the local changes in pH associated with the disease, a pH sensitive 
polymer system containing an amino residue such as (β-amino ester) PAE or (poly 
dimethyl amino ethyl methacrylate) PDMAEMA would be an ideal candidate for 
developing a delivery vehicle for fetuin therapy The slightly acidic local environment, 
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characteristic to arteriosclerosis, could be used as a stimulant for protein release. Taking 
advantage of the unique ability of polymersomes to encapsulate hydrophilic compounds 
within their core and simultaneously have active moieties such as antibodies, proteins, 
vitamins, carbohydrates and more conjugated to their surface [99], we could direct the 
release of fetuin-A to sites of calcification.  
There are several options for moving forward with this project. As the acidic 
residues of fetuin are responsible for binding with calcium mineral [83], protein 
modification is a plausible avenue to pursue in attempts to make fetuin-A therapy even 
more effective at removing unwanted mineral and or aiding in the ability of the protein to 
solubilize the mineral component. Biochemical modification of proteins (i.e. amination) 
may be the key to enhance fetuin-A ability to bind calcium mineral and increase its 
stabilizing effects on mineral growth without compromising the proteins native ability for 
cellular uptake and clearance of mineral complexes [100]. 
Though the focus of this thesis work has centered on utilizing the acidic residues 
of the protein and the slightly acidic microenvironment as a stimulus for targeting and 
release of a fetuin/MGP therapy other options do exist. As fetuin is sequestered to areas 
of vascular calcification naturally one group of researchers have developed fluorescently 
labeled fetuin to be used as a diagnostic for detecting calcified lesions [101]. In vivo 
studies have already shown much promise for the use of Alexa fluor tagged fetuin protein 
to detect calcification. The fluorescently labeled fetuin was successfully injected into the 
arteries of atherosclerotic mice models and upon excision of the arteries was detected in 
the tunica media of the carotid arteries [100, 101]. In addition to the novel use of fetuin to 
diagnose and detect calcification, this study is proof that an injectable fetuin therapy 
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would work to target arteriosclerosis. Further development of the therapeutic aspect of 
fetuin could be coupled with this existing bioluminescence to develop a theranostic use of 





1. Roger, V.L., et al., Heart disease and stroke statistics--2012 update: a report from 
the American Heart Association. Circulation, 2012. 125(1): p. e2-e220. 
2. Shea, M.K. and R.M. Holden, Vitamin K status and vascular calcification: 
evidence from observational and clinical studies. Adv Nutr, 2012. 3(2): p. 158-65. 
3. Wang, A.Y. and K.N. Lai, Use of cardiac biomarkers in end-stage renal disease. 
J Am Soc Nephrol, 2008. 19(9): p. 1643-52. 
4. Nicholas, S.B., Cardiac biomarkers and prediction of ESRD. Am J Kidney Dis, 
2011. 58(5): p. 689-91. 
5. Anand, D.V., et al., The relationship between plasma osteoprotegerin levels and 
coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll 
Cardiol, 2006. 47(9): p. 1850-7. 
6. Anand, D.V., et al., Determinants of progression of coronary artery calcification 
in type 2 diabetes role of glycemic control and inflammatory/vascular 
calcification markers. J Am Coll Cardiol, 2007. 50(23): p. 2218-25. 
7. Desai, A.S., et al., Association between cardiac biomarkers and the development 
of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. Am J 
Kidney Dis, 2011. 58(5): p. 717-28. 
8. Evrard, S., et al., Vascular calcification: from pathophysiology to biomarkers. 
Clinica Chimica Acta, 2015. 438(0): p. 401-414. 
9. Lee, C.-T., et al., Biomarkers associated with vascular and valvular calcification 
in chronic hemodialysis patients. Disease Markers, 2013. 34(4): p. 229-235. 
10. Mailloux, L., et al., The Impact of Co-Morbid Risk Factors at the Start of Dialysis 
Upon the Survival of ESRD Patients. ASAIO Journal, 1996. 42: p. 164-169. 
11. Moe, S.M. and N.X. Chen, Pathophysiology of vascular calcification in chronic 
kidney disease. Circ Res, 2004. 95(6): p. 560-7. 
12. Shroff, R.C., et al., Dialysis accelerates medial vascular calcification in part by 
triggering smooth muscle cell apoptosis. Circulation, 2008. 118(17): p. 1748-57. 
 
47 
13. Shroff, R.C. and C.M. Shanahan, VASCULAR CALCIFICATION IN 
PATIENTS WITH KIDNEY DISEASE: The Vascular Biology of Calcification. 
Seminars in Dialysis, 2007. 20(2): p. 103-109. 
14. Burke, A.P., F.D. Kolodgie, and R. Virmani, Fetuin-A, valve calcification, and 
diabetes: what do we understand? Circulation, 2007. 115(19): p. 2464-7. 
15. Dautova, Y., et al., Fetuin-a and albumin alter cytotoxic effects of calcium 
phosphate nanoparticles on human vascular smooth muscle cells. PLoS One, 
2014. 9(5): p. e97565. 
16. Jahnen-Dechent, W., et al., Mineral chaperones: a role for fetuin-A and 
osteopontin in the inhibition and regression of pathologic calcification. J Mol Med 
(Berl), 2008. 86(4): p. 379-89. 
17. Jono, S., et al., Vascular calcification in chronic kidney disease. J Bone Miner 
Metab, 2006. 24(2): p. 176-81. 
18. Ketteler, M., et al., Association of low fetuin-A (AHSG) concentrations in serum 
with cardiovascular mortality in patients on dialysis: a cross-sectional study. The 
Lancet, 2003. 361(9360): p. 827-833. 
19. Menon, V., et al., Relationship between C-reactive protein, albumin, and 
cardiovascular disease in patients with chronic kidney disease. American Journal 
of Kidney Diseases, 2003. 42(1): p. 44-52. 
20. Rudd, J.H., et al., Relationships among regional arterial inflammation, 
calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose 
positron-emission tomography/computed tomography imaging study. Circ 
Cardiovasc Imaging, 2009. 2(2): p. 107-15. 
21. Wang, A.Y. and J.E. Sanderson, Current perspectives on diagnosis of heart failure 
in long-term dialysis patients. Am J Kidney Dis, 2011. 57(2): p. 308-19. 
22. Stenvinkel, P., et al., Low fetuin-A levels are associated with cardiovascular 
death: Impact of variations in the gene enconding fetuin. Kidney Int, 2005. 67: p. 
2383-2392. 
23. Giachelli, C.M., et al., Regulation of vascular calcification: roles of phosphate and 
osteopontin. Circ Res, 2005. 96(7): p. 717-22. 
24. Demer, L.L. and Y. Tintut, Vascular calcification: pathobiology of a multifaceted 
disease. Circulation, 2008. 117(22): p. 2938-48. 
25. Sage, A.P., Y. Tintut, and L.L. Demer, Regulatory mechanisms in vascular 
calcification. Nat Rev Cardiol, 2010. 7(9): p. 528-536. 
 
48 
26. Moe, S.M., et al., Role of calcification inhibitors in the pathogenesis of vascular 
calcification in chronic kidney disease (CKD). Kidney International, 2005. 67(6): 
p. 2295-2304. 
27. Neven, E. and P.C. D'Haese, Vascular calcification in chronic renal failure: what 
have we learned from animal studies? Circ Res, 2011. 108(2): p. 249-64. 
28. Wu, M., C. Rementer, and C.M. Giachelli, Vascular calcification: an update on 
mechanisms and challenges in treatment. Calcif Tissue Int, 2013. 93(4): p. 365-
73. 
29. Shioi, A. and Y. Nishizawa, Vascular Calcification: Osteogenic Transformation 
of Vascular Smooth Muscle Cells. Journal of Oral Biosciences, 2010. 52(1): p. 26-
32. 
30. Persy, V. and P. D’Haese, Vascular calcification and bone disease: the 
calcification paradox. Trends in Molecular Medicine, 2009. 15(9): p. 405-416. 
31. Schurgers, L.J., et al., The circulating inactive form of matrix gla protein is a 
surrogate marker for vascular calcification in chronic kidney disease: a 
preliminary report. Clin J Am Soc Nephrol, 2010. 5(4): p. 568-75. 
32. SCHURGERS, L.J., et al., Post-translational modifications regulate matrix Gla 
protein function: importance for inhibition of vascular smooth muscle cell 
calcification. Journal of Thrombosis and Haemostasis, 2007. 5: p. 2503-2511. 
33. Hosaka, N., et al., Elastin degradation accelerates phosphate-induced 
mineralization of vascular smooth muscle cells. Calcif Tissue Int, 2009. 85(6): p. 
523-9. 
34. Nakano-Kurimoto, R., et al., Replicative senescence of vascular smooth muscle 
cells enhances the calcification through initiating the osteoblastic transition. Am J 
Physiol Heart Circ Physiol, 2009. 297(5): p. H1673-84. 
35. Pai, A., et al., Elastin degradation and vascular smooth muscle cell phenotype 
change precede cell loss and arterial medial calcification in a uremic mouse model 
of chronic kidney disease. Am J Pathol, 2011. 178(2): p. 764-73. 
36. Shanahan, C.M., et al., Medial Localization of Mineralization-Regulating Proteins 
in Association With Monckeberg s Sclerosis : Evidence for Smooth Muscle Cell-
Mediated Vascular Calcification. Circulation, 1999. 100(21): p. 2168-2176. 
37. Yonova, D., Vascular calcification and metabolic acidosis in end stage renal 
disease. HIPPOKRATIA, 2009. 13(3): p. 139-140. 
 
49 
38. Wajih, N., et al., Processing and transport of matrix gamma-carboxyglutamic acid 
protein and bone morphogenetic protein-2 in cultured human vascular smooth 
muscle cells: evidence for an uptake mechanism for serum fetuin. J Biol Chem, 
2004. 279(41): p. 43052-60. 
39. Hirota, S.I., Masami;  Kohri, Kenjiro;  Ito, Akihiko; Morii, Eiichi ; Adachi, Shiro;  
Kim, Hyung-Min;  Kitamura, Yukihiko; Yutani, Chikao; and  Nomura, Shintaro, 
Expression of Osteopontin Messenger RNA by Macrophages in Atherosclerotic 
Plaques. Am J Pathol, 1993. 143(4): p. 1003-1000-8. 
40. Lomashvili, K.A., Phosphate-Induced Vascular Calcification: Role of 
Pyrophosphate and Osteopontin. Journal of the American Society of Nephrology, 
2004. 15(6): p. 1392-1401. 
41. Neven, E., et al., Cell biological and physicochemical aspects of arterial 
calcification. Kidney Int, 2011. 79(11): p. 1166-77. 
42. Cranenburg, E.C., et al., Characterisation and potential diagnostic value of 
circulating matrix Gla protein (MGP) species. Thromb Haemost, 2010. 104(4): p. 
811-22. 
43. Heiss, A., et al., Structural basis of calcification inhibition by alpha 2-HS 
glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem, 
2003. 278(15): p. 13333-41. 
44. Szweras, M., et al., alpha 2-HS glycoprotein/fetuin, a transforming growth factor-
beta/bone morphogenetic protein antagonist, regulates postnatal bone growth and 
remodeling. J Biol Chem, 2002. 277(22): p. 19991-7. 
45. Mori, K., M. Emoto, and M. Inaba, Fetuin-A: A Multifunctional Protein. Recent 
Patents on Endocrine, Metabolic & Immune Drug Discovery, 2011. 5: p. 124-146. 
46. Reynolds, J.L., et al., Multifunctional roles for serum protein fetuin-a in inhibition 
of human vascular smooth muscle cell calcification. J Am Soc Nephrol, 2005. 
16(10): p. 2920-30. 
47. Barreto, F.C., et al., Effects of uremic toxins on vascular and bone remodeling. 
Semin Dial, 2009. 22(4): p. 433-7. 
48. Chen, N.X., et al., The mechanisms of uremic serum-induced expression of bone 
matrix proteins in bovine vascular smooth muscle cells. Kidney Int, 2006. 70(6): 
p. 1046-53. 
49. Lopez, I., et al., The effect of calcitriol, paricalcitol, and a calcimimetic on 
extraosseous calcifications in uremic rats. Kidney Int, 2008. 73(3): p. 300-7. 
 
50 
50. Diseases, N.I.o.D.a.D.a.K., Kidney Disease Statistics for the United States, 
U.S.D.o.H.a.H. Services, Editor. 2012, National Institutes of Health: Bethesda, 
MD. 
51. Chen, N.X., et al., Fetuin-A uptake in bovine vascular smooth muscle cells is 
calcium dependent and mediated by annexins. Am J Physiol Renal Physiol, 2006. 
292: p. F599-F606. 
52. Lee, D., Vascular calcification: Inducers and inhibitors. Materials Science and 
Engineering: B, 2011. 176(15): p. 1133-1141. 
53. Jahnen-Dechent, W., et al., Mineral chaperones: a role for fetuin-A and 
osteopontin in the inhibition and regression of pathologic calcification. Journal of 
Molecular Medicine, 2008. 86(4): p. 379-389. 
54. Theuwissen, E., E. Smit, and C. Vermeer, The role of vitamin K in soft-tissue 
calcification. Adv Nutr, 2012. 3(2): p. 166-73. 
55. Luo, G., et al., Spontaneous calcification of arteries and cartilage in mice lacking 
matrix GLA protein. Nature, 1997. 386(6620): p. 78-81. 
56. Spronk, H.M., et al., Matrix Gla protein accumulates at the border of regions of 
calcification and normal tissue in the media of the arterial vessel wall. Biochem 
Biophys Res Commun, 2001. 289(2): p. 485-90. 
57. Kovesdy, C.P., Metabolic acidosis and kidney disease: does bicarbonate therapy 
slow the progression of CKD? Nephrol Dial Transplant, 2012. 27(8): p. 3056-62. 
58. Eiji Saito, H.W., Fumiaki Sato, Hideki Sugitani, and Yoshiyuki Seyama, 
Treatment with Vitamin K2 Combined with Bisphosphonates Synergistically 
Inhibits Calcification in Cultured Smooth Muscle Cells. Journal of 
Atherosclerosis and Thrombosis, 2007. 14(6): p. 317-324. 
59. Price, P.A. and J.E. Lim, The inhibition of calcium phosphate precipitation by 
fetuin is accompanied by the formation of a fetuin-mineral complex. J Biol Chem, 
2003. 278(24): p. 22144-52. 
60. Delong, R.K., et al., Functionalized gold nanoparticles for the binding, 
stabilization, and delivery of therapeutic DNA, RNA, and other biological 
macromolecules. Nanotechnol Sci Appl, 2010. 3: p. 53-63. 
61. Lee, J. and H.-s. Yun, Hydroxyapatite-containing gelatin/chitosan microspheres 
for controlled release of lysozyme and enhanced cytocompatibility. Journal of 
Materials Chemistry B, 2014. 2(9): p. 1255. 
62. Pasch, A., et al., Nanoparticle-based test measures overall propensity for 
calcification in serum. J Am Soc Nephrol, 2012. 23(10): p. 1744-52. 
 
51 
63. Wald, J., et al., Formation and stability kinetics of calcium phosphate-Fetuin-A 
colloidal particles probed by time-resolved dynamic light scattering. 
Supplementary Material (ESI) for Soft Matter, 2011. 
64. Yamamoto, Y., et al., Effects of Peptides on CaCO3 Crystallization:  
Mineralization Properties of an Acidic Peptide Isolated from Exoskeleton of 
Crayfish and Its Derivatives. Crystal Growth & Design, 2008. 8(11): p. 4062-
4065. 
65. Haglund, A., B. Ek, and P. Ek, Phosphorylation of human plasma α2-Heremans–
Schmid glycoprotein (human fetuin) in vivo. Biochem. J, 2001. 357: p. 437-445. 
66. Won, Y.-H., et al., Multifunctional calcium carbonate microparticles: Synthesis 
and biological applications. Journal of Materials Chemistry, 2010. 20(36): p. 
7728. 
67. Legodi, M.A., et al., Rapid determination of CaCO3 in mixtures utilising FT—IR 
spectroscopy. Minerals Engineering, 2001. 14(9): p. 1107-1111. 
68. Ganim, Z., et al., Amide I Two-Dimensional Infrared Spectroscopy of Proteins. 
Accounts of Chemical Research, 2008. 41(3): p. 432-441. 
69. Barth, A., Infrared spectroscopy of proteins. Biochimica et Biophysica Acta 
(BBA) - Bioenergetics, 2007. 1767(9): p. 1073-1101. 
70. Chittur, K.K., FTIR/ATR for protein adsorption to biomaterial surfaces. 
Biomaterials 1998. 19: p. 357-369. 
71. Haris, P.I. and F. Severcan, FTIR spectroscopic characterization of protein 
structure in aqueous and non-aqueous media. Journal of Molecular Catalysis B: 
Enzymatic, 1999. 7: p. 207-221. 
72. Barth, A., The infrared absorption of amino acid side chains. Prog Biophys Mol 
Biol, 2000. 74(3-5): p. 141-73. 
73. Gruian, C., et al., FTIR and XPS studies of protein adsorption onto functionalized 
bioactive glass. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 
2012. 1824(7): p. 873-881. 
74. Djebaili, K., et al., XPS, FTIR, EDX, and XRD Analysis of Al2O3 Scales Grown 
on PM2000 Alloy. Journal of Spectroscopy, 2015. 2015: p. 16. 
75. Patel, M.M., et al., Mucin/Poly(acrylic acid) Interactions:  A Spectroscopic 
Investigation of Mucoadhesion. Biomacromolecules, 2003. 4(5): p. 1184-1190. 
 
52 
76. Stipp, S.L. and M.F. Hochella Jr, Structure and bonding environments at the 
calcite surface as observed with X-ray photoelectron spectroscopy (XPS) and low 
energy electron diffraction (LEED). Geochimica et Cosmochimica Acta, 1991. 
55(6): p. 1723-1736. 
77. Landis, W.J. and J.R. Martin, X‐ray photoelectron spectroscopy applied to gold‐
decorated mineral standards of biological interest. Journal of Vacuum Science 
&amp; Technology A, 1984. 2(2): p. 1108-1111. 
78. Barr, T.L. and S. Seal, Nature of the use of adventitious carbon as a binding 
energy standard. Journal of Vacuum Science &amp; Technology A, 1995. 13(3): 
p. 1239-1246. 
79. Ray, S. and A.G. Shard, Quantitative Analysis of Adsorbed Proteins by X-ray 
Photoelectron Spectroscopy. Analytical Chemistry, 2011. 83(22): p. 8659-8666. 
80. Vanea, E., K. Magyari, and V. Simon, Protein attachment on aluminosilicates 
surface studied by XPS and FTIR spectroscopy. Journal of Optoelectronics and 
Advanced Materials, 2010. 12(5): p. 1206. 
81. Setiawan, L.D., H. Baumann, and D. Gribbin, Surface studies of keratin fibers and 
related model compounds using ESCA. I—intermediate oxidation products of the 
model compound 1-cystine and their hydrolytical behaviour. Surface and 
Interface Analysis, 1985. 7(4): p. 188-195. 
82. Carvalho, I., et al., Influence of culture media on the physical and chemical 
properties of Ag–TiCN coatings. Journal of Physics D: Applied Physics, 2014. 
47(33): p. 335401. 
83. Russell, B.G., et al., Surface structure of human mucin using X-ray photoelectron 
spectroscopy. Biospectroscopy, 1998. 4(4): p. 257-266. 
84. Peng, H.-H., et al., Physicochemical and Biological Properties of Biomimetic 
Mineralo-Protein Nanoparticles Formed Spontaneously in Biological Fluids. 
Small, 2013. 9(13): p. 2297-2307. 
85. Shannahan, J.H., et al., Comparison of Nanotube–Protein Corona Composition in 
Cell Culture Media. Small, 2013. 9(12): p. 2171-2181. 
86. Nudelman, F., et al., The role of collagen in bone apatite formation in the 
presence of hydroxyapatite nucleation inhibitors. Nat Mater, 2010. 9(12): p. 1004-
1009. 
87. Addadi, L. and S. Weiner, Interactions between acidic proteins and crystals: 
stereochemical requirements in biomineralization. Proceedings of the National 
Academy of Sciences, 1985. 82(12): p. 4110-4114. 
 
53 
88. Gago-Duport, L., et al., Amorphous calcium carbonate biomineralization in the 
earthworm’s calciferous gland: Pathways to the formation of crystalline phases. 
Journal of Structural Biology, 2008. 162(3): p. 422-435. 
89. Heiss, A., et al., Structural basis of calcification inhibition by α2-HS 
glycoprotein/fetuin-A: Formation of colloidal calciprotein particles. Journal of 
Biological Chemistry, 2003. 278(15): p. 13333-13341. 
90. Schmid, F.-X., Biological Macromolecules: UV-visible Spectrophotometry, in 
Encyclopedia of Life Sciences. 2001, Macmillan Publishers LTD. 
91. Heiss, A., et al., Fetuin-A Is a Mineral Carrier Protein: Small Angle Neutron 
Scattering Provides New Insight on Fetuin-A Controlled Calcification Inhibition. 
Biophysical Journal, 2010. 99(12): p. 3986-3995. 
92. Heiss, A., et al., Hierarchical role of fetuin-A and acidic serum proteins in the 
formation and stabilization of calcium phosphate particles. J Biol Chem, 2008. 
283(21): p. 14815-25. 
93. Robert G Fassett, S.K.V., Glenda C Gobe, Jeff S Coombes, Matthew A Cooper, 
Wendy E Hoy, Biomarkers in Chronic Kidney Disease: A Review. Kidney Int. , 
2011. 80(8): p. 806-821. 
94. Giachelli, C.M., et al., Vascular calcification and inorganic phosphate. Am J 
Kidney Dis, 2001. 38(4 Suppl 1): p. S34-7. 
95. Tomasello, S., Secondary Hyperparathyroidism and Chronic Kidney Disease. 
Diabetes Spectrum, 2008. 21(1): p. 19-25. 
96. Alam, M.U., et al., Calcification is associated with loss of functional calcium-
sensing receptor in vascular smooth muscle cells. Cardiovasc Res, 2009. 81(2): p. 
260-8. 
97. Wallin, R., L.J. Schurgers, and R.F. Loeser, Biosynthesis of the vitamin K-
dependent matrix Gla protein (MGP) in chondrocytes: a fetuin-MGP protein 
complex is assembled in vesicles shed from normal but not from osteoarthritic 
chondrocytes. Osteoarthritis Cartilage, 2010. 18(8): p. 1096-103. 
98. Wu, C.Y., et al., Fetuin-A/albumin-mineral complexes resembling serum calcium 
granules and putative nanobacteria: demonstration of a dual inhibition-seeding 
concept. PLoS One, 2009. 4(11): p. e8058. 
99. LoPresti, C., et al., Polymersomes: nature inspired nanometer sized 
compartments. Journal of Materials Chemistry, 2009. 19(22): p. 3576. 
 
54 
100. Maharem, D.A., et al., Association of serum fetuin-A and fetuin-A gene 
polymorphism in relation to mineral and bone disorders in patients with chronic 
kidney disease. Egyptian Journal of Medical Human Genetics, 2013. 14(4): p. 
337-352. 
101. Kinkeldey, A., et al., Fetuin-A based in vivo imaging of calcified lesions. Bone. 






ADDITIONAL SPECTROSCOPY ANALYSIS 
 
56 
Fourier Transform Infrared Spectroscopy of Fetuin-A Protein 
A summary on the finding of infrared absorption characterization for Fetuin-A are 
displayed in Figure A.1 with specific functional groups summarized in Table A.2. The 
broad band corresponding to primary amine symmetric/asymmetric stretch vibration was 
identified near ~3300 cm-1. This band is characteristic of glycoproteins (i.e. fetuin-A) 
(69). The peaks seen at 2960 ad 2935 cm-1 are representative of asymmetric and 
symmetric –CH2 methylene absorption bands (69). More methylene absorption bands 
were seen in the fingerprint region, as indicated by peaks at 1453, 1379, and 860 cm-1.  
Infrared regions of interest for protein identification are that of Amide I, II and III.  For 
the fetuin-A spectra the amine I band was identified at 1652 cm-1 which can be attributed 
to C=O stretching vibrations and is useful in determining alterations on protein secondary 
structure (69). The Amide II and II regions for fetuin-A were observed at 1547 and 1238 
cm-1 wavelengths respectively. The Amide II and III bands are primarily caused by the 









Table A.1 Corresponding band assignments for neat Fetuin-A FTIR spectra. 
Assignment Origin  Absorption Band (cm-1) 
H-C(COOH), out-of-plane bending 
deformation  
C–H  860 
Primary amine, stretch, secondary α-
carbon of amino acids  
C–N  1034 
Primary amine, stretch, primary α-
carbon of amino acids  
C–N  1078 
Saturated secondary alcohol, 
deformation 
O–H  1125 
Saturated tertiary alcohol, deformation  O–H  1153 
Amide III band, secondary amine N–H  1238 
–CO stretch, carboxylic acids or 
primary alcohols  
C–O  1272 
–CH3 symmetric in-plane bending 
vibration  
C–H  1379 
–CH2 deformation, symmetric stretch, 
–CH3 asymmetrical bending vibration. 
C–H  1453 
Amino acid chain absorption, tyrosine, 
tyr–OH  
C–O  1515 
Amide II band, N–H deformation N–H  1547 
Primary amine, deformation  N–H  1634 
Amide I band, carbonyl stretch  C=O  1652 
–CH3 symmetric stretch  C–H  2875 
–CH2 symmetric stretch C–H  2935 
–CH2 asymmetric stretch  C–H  2960 
Primary amine, symmetric and/or 
asymmetric region. O–H stretching 
vibrations 




Energy Dispersive X-ray Spectroscopy of Calcified Human Vascular Smooth 
Muscle Cells 
 
Figure A.2 EDS mapping for the universal control human vascular smooth muscle 
cells.  
Elemental composition of Carbon, Oxygen and Nitrogen were detected at 72.54, 9.98, 
and 17.47 [wt. %]. 
 
Figure A.3 EDS mapping for the calcified human vascular smooth muscle cells.  
Elemental composition of Carbon, Oxygen and Nitrogen at 61.00, 16.14, and 22.86 [wt. 
%]. 
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Figure A.4 EDS mapping for the fetuin treated human vascular smooth muscle cells.  
Elemental composition of Carbon, Oxygen and Nitrogen at 62.59, 13.13, and 24.29 [wt. 
%]. 
 
Figure A.5 EDS  mapping for the vitamin K2 treated human vascular smooth muscle 
cells.  
Elemental composition of Carbon, Oxygen and Nitrogen at 66.01, 12.87, and 21.12 [wt. 
%]. 
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Figure A.6 EDS mapping for the fetuin/vitamin K2 treated human vascular smooth 
muscle cells. 
Elemental composition of Carbon, Oxygen and Nitrogen at 66.92, 14.26, and 18.82 [wt. 
%]. 
The results of the EDS (Figures A.2-A.6) did not show any detection of elemental 
calcium, though various areas of interest were analyzed. Nevertheless, the initiation of 
mineral deposition involves exosomes, and matrix vesicles that contain unstable protein 
mineral complexes. It is plausible that the fetuin and vitamin K2 treatments have formed 
stabilized protein mineral complexes around nascent biomineral therefore the deposits are 
visible in SEM but protein binding to calcium content prevents elemental detection of 
calcium mineral via EDS. 
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